Drug intelligence / Profile preview

elzasonan + sertraline

Development stage
Discontinued
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

A combination of **elzasonan** (also known as CP-448,187) and **sertraline**. Elzasonan is an investigational small-molecule drug developed as a selective antagonist of serotonin 5-HT1B and 5-HT1D receptors, developed by Pfizer. Sertraline is an established selective serotonin reuptake inhibitor (SSRI) widely used in treating depression and other mood disorders. This combination has been evaluated in clinical trials for potential enhanced antidepressant efficacy in major depressive disorder compared to sertraline (Zoloft) monotherapy. The rationale is that elzasonan's serotonin receptor antagonism may augment the serotonergic effects of sertraline, based on mechanisms involving presynaptic serotonergic modulation[1].

Other names
sertralineelzasonan
02

Targets

HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)ADRA1A (α1A)

Beyond the preview

Go deeper on elzasonan + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on elzasonan + sertraline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call